Siu, L. L. Et Al. 2018. KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma. Annual Meeting of the American-Association-for-Cancer-Research (AACR) , (Illinois, United States Of America).

Siu, L. L., Licitra, L., Tao, Y. G., Yen, C., Rischin, D., Waldron, J., ... Burtness, B.(2018). KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma . Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, United States Of America

Siu, Lillian Et Al. "KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma," Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, United States Of America, 2018

Siu, Lillian L. Et Al. "KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma." Annual Meeting of the American-Association-for-Cancer-Research (AACR) , Illinois, United States Of America, 2018

Siu, L. L. Et Al. (2018) . "KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma." Annual Meeting of the American-Association-for-Cancer-Research (AACR) , Illinois, United States Of America.

@conferencepaper{conferencepaper, author={Lillian L. Siu Et Al. }, title={KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma}, congress name={Annual Meeting of the American-Association-for-Cancer-Research (AACR)}, city={Illinois}, country={United States Of America}, year={2018}}